Biotek-snakken — December 2022
-
Is Biogen's Stock Too Risky to Invest in? https://www.proinvestor.com/investornyt/920686/is-biogens-stock-too-risky-to-invest-in
-
65 patienter har slutfört SPARKLE-studien
Pressmeddelande i aktien Ascelia Pharma. Ascelia Pharma AB (publ) (ticker: ACE), ett biofarmaceutiskt bolag inriktat på att förbättra livet för personer som lever med sällsynt förekommande cancer, meddelade idag att per den 29 december 2022, har 65 patienter slutfört den registreringsgrundande kliniska fas 3-studien SPARKLE med ledande läkemedelskandidaten Orviglance.
Börskollen (www.borskollen.se)
-
godt at se flere patienter er kommet til Ascelia Pharmas SPARKLE studie således at feb/marts ser ud til at kunne nåes
-
-
Why BioNTech Was a Sickly Stock This
Week https://www.proinvestor.com/investornyt/921824/why-biontech-was-a-sickly-stock-this-week
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind